PTX-022

Phase 2Small molecule

PPalvella Therapeutics, Inc.

PTX-022 is one of 48 small molecule programs targeting Basal Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Basal Cell CarcinomaActive, not recruiting

Lymphatic MalformationActive, not recruiting

Pachyonychia CongenitaActive, not recruiting

Basal Cell CarcinomaPhase 2

Active, not recruiting

Lymphatic MalformationPhase 2

Active, not recruiting

Pachyonychia CongenitaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

70 competitors in Basal Cell Carcinoma

#DrugCompanyPhaseTrials

Erivedge

Roche

Approved

21 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Opdivo

3 4

Yervoy

Bristol-Myers Squibb

Phase 2

1 5

Voltaren

Novartis

Phase 2

1 6

Rocaltrol

Alnylam Pharmaceuticals

Phase 2

1 7

Opdualag

Bristol-Myers Squibb

Phase 2

1 8

Fabhalta

Regeneron

Phase 2

1 9

Verteporfin PDT

Novartis

Phase 3

1 10

Sporanox

SSebela Pharmaceuticals Development LLC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pachyonychia Congenita3 trials

VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita

Completed·PPalvella Therapeutics, Inc.·Phase 3·NCT04520750·36 enrolled

A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita

Recruiting·PPalvella Therapeutics, Inc.·Phase 3·NCT05643872·45 enrolled

Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

Completed·PPalvella Therapeutics, Inc.·Phase 2/3·NCT03920228·73 enrolled

Lymphatic Malformation1 trial

Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations

Completed·PPalvella Therapeutics, Inc.·Phase 2·NCT05050149·12 enrolled

Basal Cell Carcinoma1 trial

CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

Completed·PPalvella Therapeutics, Inc.·Phase 2·NCT04893486·73 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for PTX-022. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PTX-022 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PTX-022. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Palvella Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPalvella Therapeutics, Inc.

PTX-022

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pachyonychia Congenita3 trials

Lymphatic Malformation1 trial

Basal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News